24-Jan-2011 - inVentiv Health is to acquire i3 and Campbell Alliance and realign into three operating units: clinical, consulting and commercial.
20-Jan-2011 - CRI Worldwide has acquired Lifetree Clinical Research to double its Phase I capacity and expand therapeutic expertise.
17-Jan-2011 - Dublin, Ireland-based contract research organisation (CRO) Icon has bought Oxford Outcomes, expanding its late Phase research business.
10-Jan-2011 - AMRI has combined its discovery R&D and chemistry units into a single unit it claims will benefit customers.
22-Dec-2010 - The contract service market failed to recover as hoped in 2010 and consequently many companies made cutbacks. Outsourcing-Pharma rounds up five of the most read of 2010.
21-Dec-2010 - Outsourcing-Pharma presents a round up five of our top articles on strategic partnering, which continued apace in 2010, including deals by Covance, PPD and Parexel.
13-Dec-2010 - PRA has relocated its Poland-based early development services and product registration teams into a larger shared office after achieving “solid increases in the placement of clinical studies”.
01-Dec-2010 - US based healthcare distributer, Cardinal Health, has announced the $470m acquisition of privately held healthcare distribution business Zuellig Pharma China, known locally as Yong Yu.
10-Nov-2010 - Kendle recorded a 64 per cent drop in Q3 operating income and expects its strategic review of early stage, which will establish a fair value and consider all options, to...
19-Oct-2010 - Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
04-Oct-2010 - BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
30-Sep-2010 - Covance has inked a 10-year strategic alliance, worth up to $2.2bn, with Sanofi-Aventis and acquired two European sites from the big pharma.
23-Sep-2010 - DSM aims to keep pace with the rapid evolution of pharmaceutical sector through increased partnering and a focus on Asia.
01-Sep-2010 - ImmunoSolv is merging with Grampian BioConsultants (GBC) and plans to accelerate development of the contract research business.
18-Aug-2010 - Encorium cut its operating loss to $775,000 in the second quarter despite posting a 17 per cent drop in total revenue.
16-Aug-2010 - Pre-clinical ADME contractor Cyprotex upbeat about 2010 despite drop in profit, citing new US opportunities post-Apredica acquisition.
09-Aug-2010 - Contract research organization (CRO) Lambda Therapeutic Research has acquired Biovail’s contract research division.
05-Aug-2010 - AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
03-Aug-2010 - Bilcare to buy Ineos’ rigid polymer films business for €100m ($132m) to improve access to pharmaceutical packaging customers worldwide.
03-Aug-2010 - CRL and WuXi have both vowed to independently build their capabilities, to become integrated service providers, but reported mixed financial results.
30-Jul-2010 - Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
29-Jul-2010 - Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact...
28-Jul-2010 - Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future....
20-Jul-2010 - Encorium has bought Progenitor International Research, furthering efforts to fix its financial woes by focusing on vaccines, oncology and growth in emerging markets.
19-Jul-2010 - Major Charles River Laboratories (CRL) shareholder Jana Partners says Wuxi PharmaTech deal would generate inadequate returns, citing “industry” concerns about integration.